Table 1 Correlations of CSF C4A and C4B concentration to the Positive and Negative Syndrome Scale (PANSS) scores, and performance in the key domains of the MATRICS Consensus Cognitive Battery (MCCB)

From: Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia

  

C4A

C4B

  

FEP-nSCZ

FEP-SCZ

FEP-nSCZ

FEP-SCZ

Positive and Negative Symptom Scale; PANSS

Positive sub-scale

r

−0.035

−0.27

0.05

0.19

 

P

0.906

0.136

0.863

0.435

 

N

15

29

15

28

Negative sub-scale

r

0.10

−0.25

−0.23

0,00083

 

P

0.906

0.218

0.567

0.997

 

N

15

29

15

28

General sub-scale

r

0.04

−0.02

−0.52

0.29

 

P

0.906

0.997

0.168

0.435

 

N

15

29

15

28

MATRICS Consensus Cognitive Battery (MCCB)

TMT

r

−0.45

0.05

0.01

−0.14

 

P

0.32

0.817

0.992

0.971

 

N

15

27

15

26

BACS-SC

r

0.19

0.15

0.01

0.0034

 

P

0.713

0.778

0.988

0.987

 

N

15

27

15

26

HVLT-R

r

0.30

0.34

0.988

0.05

 

P

0.566

0.433

0.776

0.971

 

N

15

25

15

26

WMS III SS

r

0.47

0.10

−0.06

0.07

 

P

0.320

0.798

0.988

0.971

 

N

15

27

15

26

LNS

r

0.01

−0.17

0.04

−0.06

 

P

0.977

0.751

0.776

0.971

 

N

15

27

15

26

NAB-MAZES

r

0.33

0.03

0.18

−0.03

 

P

0.566

0.987

0.988

0.971

 

N

15

27

15

26

BVMT-R

r

0.47

0.29

−0.19

−0.07

 

P

0.320

0.496

0.988

0.971

 

N

15

27

15

26

Fluency

r

−0.15

0.

−0.36

0.13

 

P

0.733

0.978

0.988

0.971

 

N

15

27

15

26

MSCEIT ME

r

−0.26

0.25

0.23

−0.16

 

P

0.583

0.729

0.988

0.971

 

N

15

27

15

26

CPT-IT

r

0.11

0.29

0.05

−0.05

 

P

0.783

0.164

0.988

0.971

 

N

15

27

15

25

  1. Data were generated from a total of 44 patients in the KaSP cohort with available data (median age = 24; interquartile range: 22–33; 16 females and 28 males). Number of included subjects are given in the table for each analysis. Correlations were performed using Spearman correlation analyses (two-sided P values corrected for multiple testing using Benjamini-Hochberg false discovery rate correction).
  2. FEP-nSCZ first-episode patients that did not develop schizophrenia, FEP-SCZ first-episode patients that developed schizophrenia
Back to article page